Post-Market Study of Low-flow ECCO2R Using PrismaLung+

Inclusion Criteria:

1. Patient age is ≥ 18 years old

2. Patient is expected to receive ECCO2R for a minimum of 24 hours

3. Patient has mild or moderate ARDS according to the Berlin definition:

• 100 mm Hg < PaO2/FiO2 ≤ 300 mm Hg, with PEEP ≥ 5 cm H2O, and

• Bilateral lung opacities not fully explained by effusions, lobar/lung collapse,or nodules, and

• Respiratory failure not fully explained by cardiac failure or fluid overload

4. Written informed consent to participate in the study from the patient, if possible,or from the identified authorized representative if the patient is unable to provideconsent.

Exclusion Criteria:

1. Patients body weight < 30 kg

2. Patients with a contraindication for systemic anticoagulation with heparin

3. Patients with a platelet count < 50,000/µL

4. Patients on MV > 7 days

5. Patients with very severe, or stage 4 (as per GOLD staging System) chronicobstructive pulmonary disease (COPD)

6. Current or history of heparin-induced thrombocytopenia

7. Patients who are pregnant and/or breastfeeding

8. Patients not expected to survive the duration of the planned study treatment period (24 hours)

9. Patients currently participating in another interventional clinical study, except ifthe patient is in an investigational medicinal product study, already in follow-upwithout further administration of study drug, and has not received anyinvestigational medicinal product within 5 half-lives